Depemokimab vs Mepolizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: IL-5 · full Asthma pipeline
Depemokimab
Marketed by GlaxoSmithKline
NCT04718389 · Phase 3 · completed
This was a large randomized, double-blind, active-controlled trial comparing depemokimab with mepolizumab or benralizumab, using the clinically meaningful primary endpoint of annualized clinically significant asthma exacerbations. The primary results were 0.57 versus 0.49 exacerbations per participant-year (rate ratio 1.16, 95% CI 0.98–1.38; p=0.079), but the record does not provide the non-inferiority margin, so it is not possible to confirm that the primary endpoint was met.
Next expected readout: February 2027 · NCT07828327 (registry estimate)
Reported efficacy
Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58) (met)
Result source: NCT04719832
Mepolizumab · Nucala
Marketed by GlaxoSmithKline
NCT01691859 · Phase 3 · completed
This was an open-label, single-arm long-term extension of the prior MEA112997 trial, enrolling 347 participants who had received at least two doses in that study. Because there was no randomization, blinding, or control group, the primary safety endpoint was descriptive rather than a comparative efficacy test, although the explicit extension design provides follow-up evidence beyond the original randomized trial. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants Who Experienced On-treatment Adverse Events (AE) and On-treatment Serious Adverse Events (SAE)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66 (met)
Result source: NCT01691508
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Depemokimab | Mepolizumab |
|---|---|---|
| Severe exacerbations, annualised rate | 0.6 vs 1.1−0.5 vs placeboNCT047181031 other result
| 0.5 vs 1.3−0.9 vs placeboNCT035621955 other results
|
| Trough FEV1, change | 0.2 vs 0.2+0.1 vs placeboNCT04718103 | —Not reported |
| ACQ-5, change | -0.8 vs -0.7−0.1 vs placeboNCT047181031 other result
| -0.8 vs -0.4−0.4 vs placeboNCT02281318 |
| OCS dose reduction | —Trial running · NCT06979323 | -50% vs 0%−50 vs placeboNCT016915081 other result
|
Severe exacerbations, annualised rate
- Depemokimab
- 0.6 vs 1.1−0.5 vs placeboNCT04718103
1 other result
- 0.5 vs 1.1 NCT04719832
- Mepolizumab
- 0.5 vs 1.3−0.9 vs placeboNCT03562195
5 other results
- 0.8 vs 1.7 NCT01691521
- 0.9 vs 1.7 NCT01691521
- 1.2 vs 2.4 NCT01000506
- 1.1 vs 2.4 NCT01000506
- 1.5 vs 2.4 NCT01000506
Trough FEV1, change
- Depemokimab
- 0.2 vs 0.2+0.1 vs placeboNCT04718103
- Mepolizumab
- —Not reported
ACQ-5, change
- Depemokimab
- -0.8 vs -0.7−0.1 vs placeboNCT04718103
1 other result
- -0.8 vs -0.8 NCT04719832
- Mepolizumab
- -0.8 vs -0.4−0.4 vs placeboNCT02281318
OCS dose reduction
- Depemokimab
- —Trial running · NCT06979323
- Mepolizumab
- -50% vs 0%−50 vs placeboNCT01691508
1 other result
- 83.8% vs 47.7% NCT00292877
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety
Coverage. Depemokimab: 12 of 12 rows · Mepolizumab: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Depemokimab Rows use multiple source trials | Mepolizumab Rows use multiple source trials |
|---|---|---|
| ACQ-5 absolute change · score No placebo or comparator arm | 0.03 score100mg SCa,b,c NCT04718389 · Phase 3 · combination · Asthma · phase 3 | -0.33 score @ 168wk100 mg SCa,b,c NCT02135692 · Phase 3 · registry result, not featured evidence |
| Exacerbation Hospitalization ED Rate Annualized event rate · per year | 0.05 vs 0.11 placebo per year @ 52wkd,a,b NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3 | 0.17 vs 0.43 placebo per year @ 52wk75 mg IVe,d,a,b NCT01000506 · Phase 2 show 2 more doses0.22 vs 0.43 placebo per year @ 52wk750 mg IV NCT01000506 · Phase 2 0.25 vs 0.43 placebo per year @ 52wk250 mg IV NCT01000506 · Phase 2 |
| FEV1 absolute change · L | 0.16 vs 0.16 placebo L @ 52wkd,a,b NCT04719832 · Phase 3 | 0.121 vs 0.06 placebo L @ 52wk*75 mg IVe,d,a,b NCT01000506 · Phase 2 · converted to L from 121 mL as posted show 5 more doses0.036 vs -0.009 placebo L @ 52wk*75 mg IV NCT01000506 · Phase 2 · converted to L from 36 mL as posted 0.115 vs 0.06 placebo L @ 52wk*750 mg IV NCT01000506 · Phase 2 · converted to L from 115 mL as posted 0.069 vs -0.009 placebo L @ 52wk*750 mg IV NCT01000506 · Phase 2 · converted to L from 69 mL as posted 0.14 vs 0.06 placebo L @ 52wk*250 mg IV NCT01000506 · Phase 2 · converted to L from 140 mL as posted 0.08 vs -0.009 placebo L @ 52wk*250 mg IV NCT01000506 · Phase 2 · converted to L from 80 mL as posted |
| FEV1 absolute change · L Extension (open-label) No placebo or comparator arm | -0.004 L @ 52wk100 mg SCe,a,b,f NCT05243680 · Phase 3 · registry result, not featured evidence show 1 more dose0.036 L @ 52wk100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence | -0.023 L @ 228wk*100 mga,b,f NCT01691859 · Phase 3 · monotherapy · converted to L from -23 mL as posted |
| Severe Exacerbation Rate Annualized event rate · per year No placebo or comparator arm | 0.57 per year @ 52wk100mg SCa,b NCT04718389 · Phase 3 · combination · Asthma · phase 3 | 0.93 per year @ 52wk100 mg SCa,b NCT01842607 · Phase 3 · registry result, not featured evidence |
| Severe Exacerbation Rate Annualized event rate · per year Extension (open-label) No placebo or comparator arm | 0.55 per year @ 52wk100 mg SCe,a,b,c NCT05243680 · Phase 3 · registry result, not featured evidence show 1 more dose0.58 per year @ 52wk100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence | 0.68 per year100 mga,b,c NCT01691859 · Phase 3 · monotherapy |
| SGRQ Total absolute change · score | -14.8 vs -12.49 placebo score @ 52wka,b NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3 1 other source trial-13.03 vs -9.67 placebo score @ 52wk NCT04719832 · Phase 3 | -14.29 vs -7.2 placebo score @ 52wk100 mga,b NCT03562195 · Phase 3 · registry result, not featured evidence |
| SGRQ Total absolute change · score No placebo or comparator arm | -0.69 score100mg SCg,a,b,c NCT04718389 · Phase 3 · combination · Asthma · phase 3 | -19 score @ 32wk100 mg SCg,a,b,c NCT02654145 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 11.2%100mg SCh NCT04718389 · Phase 3 · combination · Asthma · phase 3 show 13 more results11.4% NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3 8.5% NCT04719832 · Phase 3 5.6%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence 7%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence 1.4%Depemokimab Via Autoinjector NCT05602025 · Phase 1 · registry result, not featured evidence 1.4%Depemokimab Via SSD NCT05602025 · Phase 1 · registry result, not featured evidence 0%100mg NCT05140200 · Phase 1 · registry result, not featured evidence 10%300mg NCT05140200 · Phase 1 · registry result, not featured evidence —100mg NCT03287310 · Phase 1 · registry result, not featured evidence —300mg NCT03287310 · Phase 1 · registry result, not featured evidence —30mg NCT03287310 · Phase 1 · registry result, not featured evidence —10mg NCT03287310 · Phase 1 · registry result, not featured evidence —2mg NCT03287310 · Phase 1 · registry result, not featured evidence | n/a: no completion milestone100 mgi NCT01691859 · Phase 3 · monotherapy show 37 more results—Mepolizumab NCT01691859 · Phase 3 · monotherapy 15.7%75 mg IV NCT01000506 · Phase 2 14.7%750 mg IV NCT01000506 · Phase 2 13.8%250 mg IV NCT01000506 · Phase 2 —100 mg SC NCT01691508 · Phase 3 2.1%100 mg NCT04823585 · Phase 4 · registry result, not featured evidence 0% NCT04765722 · Phase 4 · registry result, not featured evidence 10%100 mg SC NCT04276233 · Phase 4 · registry result, not featured evidence 4.8%100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence 2.7%100 mg NCT03562195 · Phase 3 · registry result, not featured evidence 3.6%100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 1.3% NCT03099096 · Phase 3 · registry result, not featured evidence n/a: no completion milestone100 mg SC NCT02135692 · Phase 3 · registry result, not featured evidence 0%Liquid Autoinjector NCT03014674 · Phase 3 · registry result, not featured evidence 0%Liquid Safety Syringe NCT03014674 · Phase 3 · registry result, not featured evidence 1.2%Lyophilized Vial NCT03014674 · Phase 3 · registry result, not featured evidence 1.8% NCT03021304 · Phase 3 · registry result, not featured evidence 1.8%100 mg NCT02281318 · Phase 3 · registry result, not featured evidence —100 mg SC NCT02281318 · Phase 3 · registry result, not featured evidence 10.1%100 mg SC NCT01842607 · Phase 3 · registry result, not featured evidence 4.6%100 mg SC NCT01691521 · Phase 3 · registry result, not featured evidence 8.4%75 mg IV NCT01691521 · Phase 3 · registry result, not featured evidence 13.7% NCT03292588 · Phase 2 · registry result, not featured evidence 0%100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —40/100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 15.4%40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 0%75 mg IV NCT01366521 · Phase 2 · registry result, not featured evidence 8.7%250 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 6.7%125 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 4.8%12.5 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 73.7% NCT00802438 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 0.8%100mg SCh NCT04718389 · Phase 3 · combination · Asthma · phase 3 show 13 more results0.4% NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3 0% NCT04719832 · Phase 3 0.2%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence 0.5%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence —Depemokimab Via Autoinjector NCT05602025 · Phase 1 · registry result, not featured evidence —Depemokimab Via SSD NCT05602025 · Phase 1 · registry result, not featured evidence —100mg NCT05140200 · Phase 1 · registry result, not featured evidence —300mg NCT05140200 · Phase 1 · registry result, not featured evidence —100mg NCT03287310 · Phase 1 · registry result, not featured evidence —300mg NCT03287310 · Phase 1 · registry result, not featured evidence —30mg NCT03287310 · Phase 1 · registry result, not featured evidence —10mg NCT03287310 · Phase 1 · registry result, not featured evidence —2mg NCT03287310 · Phase 1 · registry result, not featured evidence | 5.5%100 mgi NCT01691859 · Phase 3 · monotherapy show 37 more results—Mepolizumab NCT01691859 · Phase 3 · monotherapy 3.3%75 mg IV NCT01000506 · Phase 2 5.8%750 mg IV NCT01000506 · Phase 2 5.3%250 mg IV NCT01000506 · Phase 2 —100 mg SC NCT01691508 · Phase 3 —100 mg NCT04823585 · Phase 4 · registry result, not featured evidence — NCT04765722 · Phase 4 · registry result, not featured evidence 1%100 mg SC NCT04276233 · Phase 4 · registry result, not featured evidence —100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence 0%100 mg NCT03562195 · Phase 3 · registry result, not featured evidence 0.3%100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 0.6% NCT03099096 · Phase 3 · registry result, not featured evidence 0.9%100 mg SC NCT02135692 · Phase 3 · registry result, not featured evidence —Liquid Autoinjector NCT03014674 · Phase 3 · registry result, not featured evidence —Liquid Safety Syringe NCT03014674 · Phase 3 · registry result, not featured evidence —Lyophilized Vial NCT03014674 · Phase 3 · registry result, not featured evidence — NCT03021304 · Phase 3 · registry result, not featured evidence 0.7%100 mg NCT02281318 · Phase 3 · registry result, not featured evidence —100 mg SC NCT02281318 · Phase 3 · registry result, not featured evidence 1.7%100 mg SC NCT01842607 · Phase 3 · registry result, not featured evidence 0.5%100 mg SC NCT01691521 · Phase 3 · registry result, not featured evidence 0%75 mg IV NCT01691521 · Phase 3 · registry result, not featured evidence — NCT03292588 · Phase 2 · registry result, not featured evidence —100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —40/100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence —40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 0%75 mg IV NCT01366521 · Phase 2 · registry result, not featured evidence 0%250 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 0%125 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 4.8%12.5 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence — NCT00802438 · Phase na · registry result, not featured evidence |
| Serious AEs | 9.4%100mg SCh NCT04718389 · Phase 3 · combination · Asthma · phase 3 show 13 more results7.6% NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3 6% NCT04719832 · Phase 3 9.1%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence 10%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence 2.9%Depemokimab Via Autoinjector NCT05602025 · Phase 1 · registry result, not featured evidence 0%Depemokimab Via SSD NCT05602025 · Phase 1 · registry result, not featured evidence 0%100mg NCT05140200 · Phase 1 · registry result, not featured evidence 0%300mg NCT05140200 · Phase 1 · registry result, not featured evidence 0%100mg NCT03287310 · Phase 1 · registry result, not featured evidence 0%300mg NCT03287310 · Phase 1 · registry result, not featured evidence 0%30mg NCT03287310 · Phase 1 · registry result, not featured evidence 0%10mg NCT03287310 · Phase 1 · registry result, not featured evidence 0%2mg NCT03287310 · Phase 1 · registry result, not featured evidence | —100 mgi NCT01691859 · Phase 3 · monotherapy show 37 more results22.8%Mepolizumab NCT01691859 · Phase 3 · monotherapy 13.1%75 mg IV NCT01000506 · Phase 2 12.2%750 mg IV NCT01000506 · Phase 2 15.8%250 mg IV NCT01000506 · Phase 2 1.4%100 mg SC NCT01691508 · Phase 3 4.3%100 mg NCT04823585 · Phase 4 · registry result, not featured evidence 0% NCT04765722 · Phase 4 · registry result, not featured evidence 3%100 mg SC NCT04276233 · Phase 4 · registry result, not featured evidence 11%100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence 12.1%100 mg NCT03562195 · Phase 3 · registry result, not featured evidence 2.3%100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 6.3%100mg NCT02555371 · Phase 3 · registry result, not featured evidence —100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 8.9%100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 11.9%100mg SC NCT02555371 · Phase 3 · registry result, not featured evidence 2.5% NCT03099096 · Phase 3 · registry result, not featured evidence 24.8%100 mg SC NCT02135692 · Phase 3 · registry result, not featured evidence 0%Liquid Autoinjector NCT03014674 · Phase 3 · registry result, not featured evidence 0%Liquid Safety Syringe NCT03014674 · Phase 3 · registry result, not featured evidence 0%Lyophilized Vial NCT03014674 · Phase 3 · registry result, not featured evidence 5.4% NCT03021304 · Phase 3 · registry result, not featured evidence —100 mg NCT02281318 · Phase 3 · registry result, not featured evidence 5.5%100 mg SC NCT02281318 · Phase 3 · registry result, not featured evidence 14.4%100 mg SC NCT01842607 · Phase 3 · registry result, not featured evidence 8.2%100 mg SC NCT01691521 · Phase 3 · registry result, not featured evidence 7.3%75 mg IV NCT01691521 · Phase 3 · registry result, not featured evidence 2.7% NCT03292588 · Phase 2 · registry result, not featured evidence 10%100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 20%100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 25%40/100 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 19.2%40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 25%40 mg SC NCT02377427 · Phase 2 · registry result, not featured evidence 0%75 mg IV NCT01366521 · Phase 2 · registry result, not featured evidence 0%250 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 0%125 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 4.8%12.5 mg SC NCT01366521 · Phase 2 · registry result, not featured evidence 0% NCT00802438 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 100mg SCh nasopharyngitis 20.6% covid-19 18.3% upper respiratory tract infection 11.4% NCT04718389 · Phase 3 · combination · Asthma · phase 3 show 13 more resultscovid-19 14.3% (placebo 14.7%) nasopharyngitis 13.1% (placebo 20.9%) upper respiratory tract infection 8.4% (placebo 4.7%) NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3 covid-19 20.4% (placebo 20.5%) nasopharyngitis 11.6% (placebo 18.9%) upper respiratory tract infection 10% (placebo 10.6%) NCT04719832 · Phase 3 100 mg SC nasopharyngitis 13.8% upper respiratory tract infection 10.7% covid-19 6.7% NCT05243680 · Phase 3 · registry result, not featured evidence 100 mg SC upper respiratory tract infection 11.9% nasopharyngitis 10% covid-19 7.1% NCT05243680 · Phase 3 · registry result, not featured evidence headache 8.6% injection site swelling 5.7% abdominal pain 4.3% NCT05602025 · Phase 1 · registry result, not featured evidence headache 10% injection site bruising 4.3% nausea 4.3% NCT05602025 · Phase 1 · registry result, not featured evidence 100mg blood creatine phosphokinase increased 80% blood uric acid increased 30% neutrophil count increased 20% NCT05140200 · Phase 1 · registry result, not featured evidence 300mg albumin urine present 50% blood creatine phosphokinase increased 40% blood uric acid increased 40% NCT05140200 · Phase 1 · registry result, not featured evidence 100mg nasopharyngitis 55.6% (placebo 16.7%) headache 33.3% (placebo 0%) back pain 22.2% (placebo 8.3%) NCT03287310 · Phase 1 · registry result, not featured evidence 300mg headache 33.3% (placebo 0%) nasopharyngitis 33.3% (placebo 16.7%) epistaxis 16.7% (placebo 0%) NCT03287310 · Phase 1 · registry result, not featured evidence 30mg nasopharyngitis 33.3% (placebo 16.7%) arthropod sting 22.2% (placebo 0%) dry skin 22.2% (placebo 0%) NCT03287310 · Phase 1 · registry result, not featured evidence 10mg dyspepsia 33.3% (placebo 0%) rib fracture 33.3% (placebo 0%) seasonal allergy 33.3% (placebo 16.7%) NCT03287310 · Phase 1 · registry result, not featured evidence 2mg nasopharyngitis 33.3% (placebo 16.7%) diarrhoea 16.7% (placebo 0%) headache 16.7% (placebo 0%) NCT03287310 · Phase 1 · registry result, not featured evidence | i viral upper respiratory tract infection 48.7% headache 28.5% upper respiratory tract infection 23.3% NCT01691859 · Phase 3 · monotherapy show 34 more results75 mg IV nasopharyngitis 22.2% (placebo 15.5%) headache 20.9% (placebo 17.4%) bronchitis 10.5% (placebo 9.7%) NCT01000506 · Phase 2 750 mg IV headache 20.5% (placebo 17.4%) nasopharyngitis 18.6% (placebo 15.5%) infusion related reaction 12.2% (placebo 6.5%) NCT01000506 · Phase 2 250 mg IV nasopharyngitis 21.7% (placebo 15.5%) headache 21.1% (placebo 17.4%) upper respiratory tract infection 11.2% (placebo 9.7%) NCT01000506 · Phase 2 100 mg SC headache 20.3% (placebo 21.2%) nasopharyngitis 14.5% (placebo 15.2%) bronchitis 10.1% (placebo 9.1%) NCT01691508 · Phase 3 100 mg musculoskeletal 4.3% (placebo 0%) nausea, headache, dizzines 2.1% (placebo 8.3%) skin-related symptom 2.1% (placebo 4.2%) NCT04823585 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 26.7% (placebo 40%) NCT04765722 · Phase 4 · registry result, not featured evidence 100 mg SC pyrexia 5% headache 3% oropharyngeal pain 3% NCT04276233 · Phase 4 · registry result, not featured evidence 100 mg SC headache 28.3% viral upper respiratory tract infection 16.6% bronchitis 13.1% NCT02654145 · Phase 4 · registry result, not featured evidence 100 mg upper respiratory tract infection 40.9% (placebo 41.7%) asthma 30.2% (placebo 54.3%) nasopharyngitis 16.8% (placebo 17.9%) NCT03562195 · Phase 3 · registry result, not featured evidence 100mg SC nasopharyngitis 4.6% (placebo 17.2%) abdominal pain 0% (placebo 0%) arthralgia 0% (placebo 2%) NCT02555371 · Phase 3 · registry result, not featured evidence 100mg nasopharyngitis 18.8% (placebo 17.2%) bronchitis 9.7% (placebo 3.3%) sinusitis 9% (placebo 6%) NCT02555371 · Phase 3 · registry result, not featured evidence 100mg SC nasopharyngitis 20% (placebo 17.2%) bronchitis 17.8% (placebo 3.3%) sinusitis 11.1% (placebo 6%) NCT02555371 · Phase 3 · registry result, not featured evidence 100mg SC nasopharyngitis 19% (placebo 17.2%) asthma 8.3% (placebo 9.3%) bronchitis 8.3% (placebo 3.3%) NCT02555371 · Phase 3 · registry result, not featured evidence nasopharyngitis 5.7% headache 5% upper respiratory tract infection 3.8% NCT03099096 · Phase 3 · registry result, not featured evidence 100 mg SC nasopharyngitis 42.2% bronchitis 18.9% upper respiratory tract infection 18.9% NCT02135692 · Phase 3 · registry result, not featured evidence headache 11.4% viral upper respiratory tract infection 3.8% fatigue 2.5% NCT03014674 · Phase 3 · registry result, not featured evidence headache 10% viral upper respiratory tract infection 7.5% fatigue 1.3% NCT03014674 · Phase 3 · registry result, not featured evidence headache 7.1% fatigue 5.9% viral upper respiratory tract infection 2.4% NCT03014674 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 7.1% NCT03021304 · Phase 3 · registry result, not featured evidence 100 mg SC headache 16.5% (placebo 21.2%) nasopharyngitis 11.4% (placebo 16.5%) upper respiratory tract infection 6.2% (placebo 5%) NCT02281318 · Phase 3 · registry result, not featured evidence 100 mg SC nasopharyngitis 30.1% upper respiratory tract infection 15.2% headache 13.4% NCT01842607 · Phase 3 · registry result, not featured evidence 100 mg SC headache 20.1% (placebo 17.3%) nasopharyngitis 17% (placebo 24.1%) upper respiratory tract infection 12.4% (placebo 14.1%) NCT01691521 · Phase 3 · registry result, not featured evidence 75 mg IV headache 24.1% (placebo 17.3%) nasopharyngitis 23.6% (placebo 24.1%) upper respiratory tract infection 11.5% (placebo 14.1%) NCT01691521 · Phase 3 · registry result, not featured evidence headache 10.3% (placebo 4.9%) injection site reaction 8.9% (placebo 0%) vomiting 8.9% (placebo 8.3%) NCT03292588 · Phase 2 · registry result, not featured evidence 100 mg SC headache 20% acne 10% alanine aminotransferase increased 10% NCT02377427 · Phase 2 · registry result, not featured evidence 100 mg SC bronchitis 30% headache 30% cough 20% NCT02377427 · Phase 2 · registry result, not featured evidence 40/100 mg SC nasopharyngitis 50% abdominal pain 25% adrenal suppression 25% NCT02377427 · Phase 2 · registry result, not featured evidence 40 mg SC injection site reaction 19.2% headache 11.5% nasopharyngitis 11.5% NCT02377427 · Phase 2 · registry result, not featured evidence 40 mg SC bronchitis 31.3% headache 25% influenza 18.8% NCT02377427 · Phase 2 · registry result, not featured evidence 75 mg IV arthralgia 18.2% asthma 9.1% back pain 9.1% NCT01366521 · Phase 2 · registry result, not featured evidence 250 mg SC headache 8.7% nasopharyngitis 8.7% abdominal distension 4.3% NCT01366521 · Phase 2 · registry result, not featured evidence 125 mg SC injection site reaction 20% asthma 6.7% dermatitis atopic 6.7% NCT01366521 · Phase 2 · registry result, not featured evidence 12.5 mg SC asthma 19% injection site reaction 14.3% nasopharyngitis 14.3% NCT01366521 · Phase 2 · registry result, not featured evidence upper respiratory infection 10.5% back pain 2.6% erythema 2.6% NCT00802438 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dTrial phases differ: Phase 2 versus Phase 3.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fAssessment timepoints differ: 228 weeks versus 52 weeks.
- gTrial phases differ: Phase 4 versus Phase 3.
- hPopulation comparability has not been reviewed for 12 of these studies.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Depemokimab
show 1 more result
show 1 more result
show 17 more results
show 3 more results
Mepolizumab
show 17 more results
show 8 more results
show 8 more results
show 2 more results
show 8 more results
show 38 more results
show 1 more result
+ 26 further endpoints in the CSV export.
Chronic Obstructive Pulmonary Disease
Shared mechanism: IL-5 · full Chronic Obstructive Pulmonary Disease pipeline
Depemokimab
Marketed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT06961214 (registry estimate)
No aligned efficacy figure on record for this race.
Mepolizumab · Nucala
Marketed by GlaxoSmithKline
NCT01463644 · Phase 3 · completed
Participants were randomly assigned and quadruple-blinded to mepolizumab or placebo, but only 18 people were enrolled. The primary endpoint was a sputum eosinophil biomarker rather than a clinical outcome, and the registry does not state whether the between-group difference was statistically significant, so the result is unclear.
Next expected readout: February 2028 · NCT07749001 (registry estimate)
Reported efficacy
Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Mepolizumab 100 mg 0.8 Exacerbations per year (95% CI 0.7 to 0.91) | Placebo 1.01 Exacerbations per year (95% CI 0.89 to 1.15) (met)
Result source: NCT04133909
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Depemokimab | Mepolizumab |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Trial running · NCT06961214 | 0.8 vs 1.0−0.2 vs placeboNCT041339094 other results
|
| Trough FEV1, change | —Trial running · NCT06961214 | —Not reported |
| SGRQ total, change | —Trial running · NCT06961214 | -2.8 vs -3+0.2 vs placeboNCT021059489 other results
|
| TDI focal score | —Trial running · NCT06961214 | —Not reported |
Moderate or severe exacerbations, annualised rate
- Depemokimab
- —Trial running · NCT06961214
- Mepolizumab
- 0.8 vs 1.0−0.2 vs placeboNCT04133909
4 other results
- 1.4 vs 1.7 NCT02105948
- 1.5 vs 1.5 NCT02105948
- 1.2 vs 1.5 NCT02105961
- 1.3 vs 1.5 NCT02105961
Trough FEV1, change
- Depemokimab
- —Trial running · NCT06961214
- Mepolizumab
- —Not reported
SGRQ total, change
- Depemokimab
- —Trial running · NCT06961214
- Mepolizumab
- -2.8 vs -3+0.2 vs placeboNCT02105948
9 other results
- -3.2 vs -4 NCT02105948
- -5 vs -3.1 NCT02105961
- -3.3 vs -3.1 NCT02105961
- 60.7 vs 62.4 NCT04075331
- 61.2 vs 60.4 NCT04075331
- 64.3 vs 61.7 NCT04075331
- 64.3 vs 63.3 NCT04075331
- 64.3 vs 64.6 NCT04075331
- 65.5 vs 66.2 NCT04075331
TDI focal score
- Depemokimab
- —Trial running · NCT06961214
- Mepolizumab
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Depemokimab: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Depemokimab: 0 of 4 rows · Mepolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Mepolizumab |
|---|---|
| Dropout rate | 0%a NCT01463644 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 show 6 more results16.1%100 mg NCT04133909 · Phase 3 8.6%100 mg NCT02105948 · Phase 3 14.7%100 mg NCT02105948 · Phase 3 7.6%100 mg SC NCT02105961 · Phase 3 · registry result, not featured evidence 13.3%300 mg SC NCT02105961 · Phase 3 · registry result, not featured evidence 26.9% NCT04075331 · Phase 2/3 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01463644 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 show 6 more results1%100 mg NCT04133909 · Phase 3 3%100 mg NCT02105948 · Phase 3 6%100 mg NCT02105948 · Phase 3 3.1%100 mg SC NCT02105961 · Phase 3 · registry result, not featured evidence 5.8%300 mg SC NCT02105961 · Phase 3 · registry result, not featured evidence — NCT04075331 · Phase 2/3 · registry result, not featured evidence |
| Serious AEs | 25%a NCT01463644 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 show 6 more results25.1%100 mg NCT04133909 · Phase 3 27.9%100 mg NCT02105948 · Phase 3 27.2%100 mg NCT02105948 · Phase 3 25.6%100 mg SC NCT02105961 · Phase 3 · registry result, not featured evidence 26.7%300 mg SC NCT02105961 · Phase 3 · registry result, not featured evidence 1.7% NCT04075331 · Phase 2/3 · registry result, not featured evidence |
| Most frequent reported AEs | a infective bronchitis 37.5% (placebo 40%) urinary tract infection 12.5% (placebo 0%) NCT01463644 · Phase 3 · monotherapy · Chronic Obstructive Pulmonary Disease · phase 3 show 6 more results100 mg covid-19 11.9% (placebo 11.7%) nasopharyngitis 10.2% (placebo 8.7%) headache 7.9% (placebo 7%) NCT04133909 · Phase 3 100 mg nasopharyngitis 16.3% (placebo 14%) headache 10.3% (placebo 13.5%) back pain 7.3% (placebo 7%) NCT02105948 · Phase 3 100 mg nasopharyngitis 14.1% (placebo 14%) headache 9.8% (placebo 13.5%) back pain 8.7% (placebo 7%) NCT02105948 · Phase 3 100 mg SC nasopharyngitis 17.5% (placebo 21.2%) headache 15.2% (placebo 8.8%) upper respiratory tract infection 7.2% (placebo 8.8%) NCT02105961 · Phase 3 · registry result, not featured evidence 300 mg SC nasopharyngitis 17.8% (placebo 21.2%) headache 9.8% (placebo 8.8%) back pain 7.6% (placebo 4.9%) NCT02105961 · Phase 3 · registry result, not featured evidence diarrhoea 10.2% (placebo 7.6%) covid-19 6.8% (placebo 5.9%) fall 6.8% (placebo 7.6%) NCT04075331 · Phase 2/3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Mepolizumab
show 4 more results
show 13 more results
show 4 more results
show 27 more results
show 9 more results
show 9 more results
+ 18 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Depemokimab's landscape · Mepolizumab's landscape